Myriad Genetics, Inc. (MYGN) Tops Q1 EPS by 1c, Reaffirms FY12 Guidance
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Join SI Premium – FREE
Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q1 EPS of $0.29, $0.01 better than the analyst estimate of $0.28. Revenue for the quarter came in at $110.5 million versus the consensus estimate of $106.49 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
- Seritage Growth Properties (SRG) Reports Q2 Loss of $0.13
- INVO Fertility (IVF) Tops Q2 EPS by 105c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
